Skip to Main Content

Alexion Pharmaceuticals said Wednesday it is buying Sweden’s Wilson Therapeutics for $855 million to expand its pipeline of drugs to treat rare diseases, as the pace of deal-making in the biotech sector ticks higher.

The centerpiece of the Alexion transaction is Wilson’s lead drug WTX101, an oral agent in Phase 3 development as a treatment for Wilson disease, a rare, inherited disorder that causes liver and neurologic problems. WTX101 works by binding to copper in the bloodstream and promoting its removal in the liver.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!